Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Expression of proliferative and preapoptotic molecules in human myometrium and leiomyoma throughout the menstrual cycle.

Kayisli UA, Berkkanoglu M, Kizilay G, Senturk L, Arici A.

Reprod Sci. 2007 Oct;14(7):678-86.

PMID:
18000229
2.

Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas.

Maruo T, Ohara N, Matsuo H, Xu Q, Chen W, Sitruk-Ware R, Johansson ED.

Contraception. 2007 Jun;75(6 Suppl):S99-103. Epub 2007 Mar 21. Review.

PMID:
17531625
3.

Both GnRH agonist and continuous oral progestin treatments reduce the expression of the tyrosine kinase receptor B and mu-opioid receptor in deep infiltrating endometriosis.

Matsuzaki S, Canis M, Pouly JL, Botchorishvili R, D├ęchelotte PJ, Mage G.

Hum Reprod. 2007 Jan;22(1):124-8. Epub 2006 Sep 25.

4.

A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.

Wang J, Ohara N, Wang Z, Chen W, Morikawa A, Sasaki H, DeManno DA, Chwalisz K, Maruo T.

Hum Reprod. 2006 Jul;21(7):1869-77. Epub 2006 Apr 13.

5.

Risk factors for clinically diagnosed uterine fibroids in women around menopause.

Parazzini F.

Maturitas. 2006 Sep 20;55(2):174-9. Epub 2006 Mar 13.

PMID:
16533580
6.

Steroid hormones and leiomyomas.

Marsh EE, Bulun SE.

Obstet Gynecol Clin North Am. 2006 Mar;33(1):59-67. Review.

PMID:
16504806
7.
9.

Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium.

Jasonni VM, La Marca A, Santini D.

Int J Gynaecol Obstet. 2005 Jun;89(3):297-8. No abstract available.

PMID:
15919406
10.

Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines.

Swartz CD, Afshari CA, Yu L, Hall KE, Dixon D.

Mol Hum Reprod. 2005 Jun;11(6):441-50. Epub 2005 May 6.

11.

Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.

Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W.

Endocr Rev. 2005 May;26(3):423-38. Epub 2005 Apr 27. Review. Erratum in: Endocr Rev. 2005 Aug;26(5):703.

PMID:
15857972
13.

Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata.

Chwalisz K, DeManno D, Garg R, Larsen L, Mattia-Goldberg C, Stickler T.

Semin Reprod Med. 2004 May;22(2):113-9. Review.

PMID:
15164306
14.

Treatment strategies for uterine leiomyoma: the role of hormonal modulation.

Cook JD, Walker CL.

Semin Reprod Med. 2004 May;22(2):105-11. Review.

PMID:
15164305
15.

Sex steroidal regulation of uterine leiomyoma growth and apoptosis.

Maruo T, Ohara N, Wang J, Matsuo H.

Hum Reprod Update. 2004 May-Jun;10(3):207-20. Review.

16.

Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells.

Yamada T, Nakago S, Kurachi O, Wang J, Takekida S, Matsuo H, Maruo T.

Hum Reprod. 2004 Apr;19(4):815-21. Epub 2004 Jan 29.

17.

Cost-effectiveness of uterine artery embolization and hysterectomy for uterine fibroids.

Beinfeld MT, Bosch JL, Isaacson KB, Gazelle GS.

Radiology. 2004 Jan;230(1):207-13. Review.

PMID:
14695395
18.

Different proliferative and apoptotic activity in peripheral versus central parts of human uterine leiomyomas.

Bourlev V, Pavlovitch S, Stygar D, Volkov N, Lindblom B, Olovsson M.

Gynecol Obstet Invest. 2003;55(4):199-204.

PMID:
12904692
20.

Estrogen receptor phosphorylation.

Lannigan DA.

Steroids. 2003 Jan;68(1):1-9. Review.

PMID:
12475718
Items per page

Supplemental Content

Write to the Help Desk